See what questions
a doctor would ask.
A company has been authorized by the European Commission to begin marketing Alimta. Alimta is the first approved chemotherapy treatment for patients with malignant pleural mesothelioma in the European Union. It has been shown to be effective and the use of folic acid and vitamin B12 alongside it reduces the side effects dramatically. Research is being conducted for use of Alimta against other cancers as well. Common side effects of Alimta when used with a common chemotherapy agent are: blood and lymphatic system disorders, gastrointestinal disorders, fatigue, sensory disorders, renal and urinary disorders, rash and hair loss.
Source: summary of medical news story as reported by Onlypunjab
About: Alimta approved for use against certain cancers in the European Union
Date: 16 October 2004
http:/ This summary article refers to the following medical categories:
Related Medical Topics
More News Topics
This summary article refers to the following medical categories:
Search Specialists by State and City